A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of Camizestrant in Post-menopausal Female Subjects

2022-502277-41-00 Protocol D8532C00002 Human pharmacology (Phase I) - Other Ended

Start 5 Jun 2023 · End 23 Feb 2024 · Status Ended · 2 EU/EEA countries · 3 sites · Protocol D8532C00002

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ended
Participants planned 28
Countries 2
Sites 3

moderate or severe hepatic impairment

Key facts

Sponsor
AstraZeneca AB
Participant type
Patients, Healthy volunteers
Age range
18-64 years, 65+ years
Gender
Female
Therapeutic area
Diseases [C] - Digestive System Diseases [C06]
Trial duration
5 Jun 2023 → 23 Feb 2024
Decision date (initial)
2023-05-25
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

moderate or severe hepatic impairment

VersionLevelCodeTermSystem organ class
22.1 LLT 10052254 Hepatic impairment 10019805

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

AstraZeneca AB

Sponsor organisation
AstraZeneca AB
Address
Astraallen Gartuna, Karlebyhus Byggnad 674 Karlebyhus Byggnad 674
City
Sodertalje
Postcode
151 85
Country
Sweden

Scientific contact point

Organisation
AstraZeneca AB
Contact name
AstraZeneca Information Center

Public contact point

Organisation
AstraZeneca AB
Contact name
AstraZeneca Information Center

Locations

2 EU/EEA countries · 3 investigational sites

By country

CountryMS statusPlanned subjectsSites
Bulgaria Ended 7 2
Slovakia Ended 7 1
Rest of world
United States
14

Investigational sites

Bulgaria

2 sites · Ended
Medical Center COMAC Medical EOOD
NA, 3, Sv. Georgi Sofiyski Str., Sofia
Medical Center Comac Medical Ltd.
NA, Triaditsa, Ulitsa Urvich 13, Sofiya

Slovakia

1 site · Ended
Summit Clinical Research s.r.o.
Zariadenie biomedicínskeho výskumu (vnútorné lekárstvo, klinická farmakológia), Bardosova 2a, 831 01, Nove Mesto

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Bulgaria 2023-07-27 2024-02-22 2023-08-24 2024-02-19
Slovakia 2023-06-05 2024-02-22 2023-06-29 2024-02-19

Application history

5 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2023-01-27 Slovakia Acceptable
2023-05-19
2023-05-19
2 SUBSTANTIAL MODIFICATION SM-1 2023-09-04 Acceptable 2023-10-23
3 NON SUBSTANTIAL MODIFICATION NSM-1 2023-12-22 Slovakia Acceptable 2023-12-22
4 NON SUBSTANTIAL MODIFICATION NSM-2 2024-01-23 Acceptable 2024-01-23
5 SUBSTANTIAL MODIFICATION SM-3 2024-01-29 Slovakia Acceptable
2024-03-18
2024-03-18